It is with great sadness and regret that the Board of Stablepharma has to announce the unexpected passing of Martin Powell on the 1st of May 2023. As our colleague and fellow Director, Martin was someone who made substantial contributions to the company since the early days and we will all miss his company, enthusiasm […]
Read More
Professor Saul Faust, consultant paediatrician at University Hospital Southampton, has been recognised for his research into vaccines which helped determine how safe and effective they were before being rolled out. He was presented the accolade by the Prince of Wales last week after it was announced last year in the Queen’s Jubilee Honour’s List. Southampton […]
Read More
Stablepharma considers IPO, Series B round to bring vaccines to market – CEO 08:00 CEST, 5 April 2023 Stablepharma, a UK developer of the world’s first fridge-free vaccines, is evaluating an IPO and a financing round to bring two vaccines to market, CEO Özgür Tuncer told Mergermarket. The business will take a decision after the summer […]
Read More
Stablepharma Ltd closed Series A funding round of $6.4m to progress the development of fridge-free vaccines and mRNA/LNP stabilisation technologies. Stablepharma Ltd, the Fridge-Free Vaccine Company closed their Series A funding round having secured a two-part £5.2m / $6.4m in total. Lead investors are Hamilton Portfolio & Oval Investments, along with CrowdCube and backing of […]
Read More
We are delighted to announce that Johnny Sutton, founder and CEO of Oval Investments, will become a member of the Board of Stablepharma Ltd. Johnny joins the Board of the ‘Fridge-free Vaccine Company’, following Oval Investments’ major participation in the Series A fundraise, recently completed on 31st October 2022. https://stablepharma.com/team/johnny-sutton/ With extensive experience within Investment […]
Read More
Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) are delighted to announce that we have signed a definitive agreement for the exclusive bulk supply and commercialisation of the Tetanus diphtheria vaccine, on September 20th, 2022. This agreement follows the head of terms signed in 2022 and consolidates the relationship between Stablepharma Ltd […]
Read More
Stablepharma and BB-NCIPD Ltd (Bul Bio) establish thermostability of StablevaX™-Td Vaccine After Exposure to +45°C for 12 months In-vitro and In-vivo Studies Pave the Way for Fridge-Free Vaccines Stablepharma Ltd and BB-NCIPD Ltd (Bul Bio) formed a strategic partnership in 2021 to produce the world’s first fridge-free Tetanus diphtheria (Td) vaccine, StablevaX™-Td. Encouraging potency and […]
Read More
June 15th, 2022 London, UK – Stablepharma Ltd., a UK-based biotechnology company pioneering fridge-free vaccines today announced a collaboration agreement with a world leader in sterile manufacturing and serving science, to manufacture thermostable Tetanus diphtheria (Td) vaccines at their facilities in Italy. “Our new partner is one of the world’s leading sterile manufacturing companies, offering a […]
Read More
As the country wound down for the long bank holiday weekend, Professor Jonathan Heeney was juggling a mountain of work in Cambridge. “The thing is, what we’re doing is really timely,” he says. For years, Heeney and his team at biotech company DIOSynVax had been working on creating a vaccine suitable for three infectious viruses […]
Read More
Stablepharma Ltd are delighted to that our CEO & Executive Director, Özgür Tuncer has been named as one of London’s most impressive and successful Directors in the Biotechnology space by Best Startup UK . Best Startup UK tracks over 130,000 UK startups and over 500,000 people who hold key positions in these companies. They use […]
Read More